HiFiBiO: FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease

(marketscreener.com) FibroGen Exclusively Licenses HiFiBiO's Galectin-9 Program, and Obtains an Exclusive Option to their CXCR5 and CCR8 ProgramsTransformative Transaction for FibroGen's Early-stage Pipeline HiFiBiO to Receive $25 Million Upfront, and Up to a Total of $1.1B in Additional Milestone Payments Across All Three Programs, Plus Royalties ...https://www.marketscreener.com/quote/stock/FIBROGEN-INC-18537026/news/FibroGen-and-HiFiBiO-Announce-Transformative-Partnership-to-Advance-Next-Generation-Therapies-for-Pa-35631540/?utm_medium=RSS&utm_content=20210617